Population pharmacokinetics and exposure–response relationship of amatuximab, an anti-mesothelin monoclonal antibody, in patients with malignant pleural mesothelioma and its application in dose selection

• Published in: Cancer chemotherapy and pharmacology Vol. 77; no. 4; pp. 733 - 743
• Main Authors: Gupta, Anubha, Hussein, Ziad, Hassan, Raffit, Wustner, Jason, Maltzman, Julia D., Wallin, Bruce A.
• Format: Journal Article
• Language: English
• Published: Berlin/Heidelberg Springer Berlin Heidelberg 01.04.2016; Springer Nature B.V
• Subjects: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal - pharmacokinetics; Antibodies, Monoclonal - therapeutic use; Cancer Research; Disease-Free Survival; Female; Humans; Lung Neoplasms - drug therapy; Lung Neoplasms - mortality; Male; Medicine; Medicine & Public Health; Mesothelioma - drug therapy; Mesothelioma - mortality; Mesothelioma, Malignant; Middle Aged; Models, Biological; Oncology; Original Article; Pharmacology/Toxicology; Pleural Neoplasms - drug therapy; Pleural Neoplasms - mortality; Monoclonal antibody; Malignant pleural mesothelioma; Population pharmacokinetic/pharmacodynamic modeling; Amatuximab

Purpose To characterize amatuximab pharmacokinetics (PK) and the relationship of amatuximab exposure with response in patients with unresectable malignant pleural mesothelioma (MPM) receiving amatuximab with pemetrexed and cisplatin. Methods A nonlinear mixed effects PK model was built using data fr...